DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models.

ABSTRACT:

Background

One of the key reasons for the high failure rate of new agents and low therapeutic benefit of approved treatments is the lack of preclinical models that mirror the biology of human tumors. At present, the optimal cancer model for drug response study to date is patient-derived xenograft (PDX) models. PDX recaptures both inter- and intra-tumor heterogeneity inherent in human cancer, which represent a valuable platform for preclinical drug testing and personalized medicine applications. Building efficient drug response analysis tools is critical but far from adequate for the PDX platform.

Results

In this work, we first classified the emerging PDX preclinical trial designs into four patterns based on the number of tumors, arms, and animal repeats in every arm. Then we

SUBMITTER: Li Q 

PROVIDER: S-EPMC6350365 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature